Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national <scp>BIOBADADERM</scp> registry

Abstract

Serious adverse events are more common in elderly patients, although they may be related to other variants that are associated with this age group and not due to the treatment itself. Use of biologics was associated with lower risk of adverse events in the whole group. We found no differences in this association between young and elderly. These results are reassuring, although uncontrolled confounding could not be excluded as an explanation for these findings, and the power of the study to detect differences was low.